摘要
他汀类药物能够降低心血管事件发生率以及死亡率,成为目前世界上最常用的药物之一,特别是他汀类药物对于2型糖尿病患者获益情况也是被大家认可的。2012年美国食品药品监督管理局发布信息称重新修改他汀类药物的说明,提到他汀类药物的使用会致空腹血糖和糖化血红蛋白会存在小幅度增加的风险,引得了许多公共关注。据估计服用他汀获益的人群中每40人就存在1人出现该风险,其发病机制尚未清楚,可能是通过影响胰岛素抵抗及细胞糖代谢。但我们明确的是服用他汀获益超过他汀可能带来的糖尿病风险。
The stains can reduce the risk of major cardiovascular events, which makes statin to be the most widely used prescription around the world. In particular, the benefit of using statin in type 2 diabetes （T2D） is well studied and understood. In 2012, the Food and Drug Administration updated statin safety label to include that statins have been associated with possible increase in HbAlc and fasting serum glucose levels. This has stirred much debate in the medical community. ItJs said that the number needed to treat for statin benefit is estimated at one in 40 depending on the population. The mechanism of this link is unknown. Statins may accelerate progression to diabetes by molecular mechanisms that impact insulin resistance and cellular metabolism of carbohydrates. It remains clear that the benefit of statin therapy outweighs the risk of developing diabetes.
出处
《中国现代医生》
2016年第26期162-164,共3页
China Modern Doctor
基金
浙江省中医药科技计划(2016ZA148)
关键词
他汀类药物
糖尿病
心血管
不良反应
Statins
Diabetes mellitus
Cardiovascular
Adverse drug reaction
